Japan IVD Quality Control Market By Offerings (Quality Control Products (Serum based ,Whole Blood ,Urine) Quality Assurance Services, Data Management Solutions) By Control (Analytes) (Immunochemistry ,Clinical Chemistry ,Microbiology ,Hematology ,Coagulation ,Infectious disease ,Diabetics/ Hemoglobin ,Cardiology ,Others) By Manufacturer Type (Dependent/First-Party Controls, Independent/Third Party Controls) By End Users (Hospitals and Clinics ,Laboratories, Research Institutes, Others); By Region (Hokkaido, Tohoku, Kanto, Chubu, Kinki/Kansai, Chugoku, Shikoku, Kyushu (incl. Okinawa)) – Japan Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031

Report ID :AMI-1628 | Category : Healthcare | Published Date : August, 2023 | Pages : 180 | Format :PDF

In vitro quality control (IVQC) is a crucial component of quality assurance in the pharmaceutical, biotechnology, and medical device industries. It involves a series of tests and procedures conducted outside the living organism (in vitro) to assess the quality, safety, and efficacy of products before they are introduced to the market or used in clinical trials. Japan IVD quality control market is expected to witness CAGR ~4.5% during 2023 – 2031.

Increasing Prevalence of Chronic Diseases: Japan IVD Quality Control Market

The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases is one of the significant drivers of the IVD quality control market in Japan. According to the World Health Organization (WHO), chronic diseases are responsible for 71% of all deaths globally. Japan has one of the world's oldest populations, with a significant proportion of elderly individuals. With increasing age comes a higher risk of developing chronic diseases such as cardiovascular diseases, diabetes, cancer, and neurodegenerative disorders. Furthermore, rapid urbanization and modernization have brought about changes in lifestyle habits in Japan. A shift toward a more sedentary lifestyle, unhealthy diets, and smoking have contributed to the rise in chronic diseases.

Growing Demand for Diagnostic Testing Services: Japan IVD Quality Control Market

As the demand for healthcare services increases, there has been a growing need for diagnostic testing services worldwide, including Japan. The rising prevalence of chronic diseases, an aging population, and increased health awareness are some of the factors driving this demand. Diagnostic testing is critical for early detection, accurate diagnosis, and effective disease management, leading to better patient outcomes and reduced healthcare costs in the long run.

In Japan, the demand for diagnostic testing services has led to a parallel growth in the In Vitro Diagnostics (IVD) industry. IVD refers to medical devices, reagents, and accessories used to perform tests on samples taken from the human body (e.g., blood, urine, tissue) to diagnose diseases or monitor health conditions. It plays a pivotal role in supporting healthcare professionals' decisions by providing them with essential information to deliver precise and targeted treatments. The IVD quality control market in Japan has become increasingly important to ensure the accuracy, reliability, and safety of diagnostic tests. Quality control measures are crucial for verifying the performance of IVD products, minimizing errors, and maintaining consistency in results across different testing facilities.

Japan IVD Quality Control Market Revenue & Forecast, (US$ Million), 2015 – 2031


Japan IVD Quality Control Market

Quality control products accounted for a substantial market share in the IVD quality control market in 2022. Quality control products are essential components in ensuring the accuracy, reliability,  and consistency of diagnostic testing in clinical laboratories and other healthcare settings. The healthcare industry in Japan emphasizes continuous improvement methodologies, such as Lean Six Sigma, to optimize processes and enhance overall quality. Quality control products support such initiatives by providing data to monitor and improve testing procedures. Additionally, advancements in quality control products, including the development of multi-analyte controls and third-party quality control materials, have contributed to their widespread adoption in the IVD market.

In the dynamic IVD quality control market in Japan, hospitals and clinics have consistently accounted for a lion's share of the market. These healthcare facilities play a crucial role in diagnostic testing, offering a wide range of medical services and requiring a robust quality control system to ensure accurate and reliable results. Hospitals and clinics serve as primary points of care for patients, diagnosing and treating various medical conditions. As a result, they heavily rely on IVD tests to aid in the diagnosis and monitoring of diseases. To maintain high standards of care, these facilities invest significantly in quality control products, such as control materials, calibrators, and proficiency testing materials.

The stringent regulatory environment in Japan emphasizes the importance of quality control in diagnostic testing. Hospitals and clinics, being responsible for patient outcomes, prioritize the implementation of effective quality control measures. This includes adherence to regulatory standards, proficiency testing programs, and ongoing performance evaluations to ensure accurate and reliable test results. The lion's share of the IVD quality control market held by hospitals and clinics is also attributed to the volume of testing conducted at these facilities. As major healthcare providers in the country, they handle a vast number of patient samples, necessitating a significant demand for quality control products to maintain accuracy and precision across their testing processes.

Furthermore, hospitals and clinics actively participate in accreditation programs and seek certifications from recognized bodies, further highlighting their commitment to quality and accuracy in diagnostic testing. These efforts reinforce the importance of quality control in their daily operations, driving the demand for IVD quality control market.

In conclusion, hospitals and clinics in Japan play a dominant role in the IVD quality control market due to their substantial testing volume, commitment to regulatory compliance, and focus on delivering accurate and reliable diagnostic services to their patients. As the demand for high-quality healthcare services continues to grow, the importance of quality control in these facilities will remain central to their operations and position in the IVD market.

Competitive Landscape

The report provides both, qualitative and quantitative research of Japan IVD quality control market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their Japan presence, competitors, service offerings and specification amongst others.

Some of the players operating in the Japan IVD quality control market are:

  • Abbott Diagnostics
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fortress Diagnostics
  • Fujirebio Inc.
  • Horiba Medical Japan Co., Ltd.
  • Randox Laboratories
  • Sekisui Medical Co., Ltd.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Other Market Participants

Japan IVD Quality Control Market

By Offerings  

  • Quality control Products
    • Serum based
    • Whole Blood
    • Urine
  • Quality Assurance Services
  • Data Management Solutions

By Control (Analytes) 

  • Immunochemistry
  • Clinical Chemistry
  • Microbiology
  • Hematology
  • Coagulation
  • Infectious disease
  • Diabetics/ Hemoglobin
  • Cardiology
  • Others

By Manufacturer Type

  • Dependent/first-party controls
  • Independent/third party controls

By End Users 

  • Hospitals and Clinics
  • Laboratories
  • Research Institutes
  • Others

By Region 

  • Hokkaido
  • Tohoku
  • Kanto
  • Chubu
  • Kinki/Kansai
  • Chugoku
  • Shikoku
  • Kyushu (incl. Okinawa)


Table of Contents

1.    Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2015 - 2021

1.2.2. Base Year: 2022

1.2.3. Forecast Years: 2023 – 2031

2.    Key Target Audiences

3.    Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Japan Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4.    Recommendations and Insights from AMI’s Perspective**

5.    Holistic Overview of IVD Quality Control Market

6.    Market Synopsis:  IVD Quality Control Market

7.    IVD Quality Control Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.3. Trends in IVD Quality Control Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: IVD Quality Control Market

7.6. Porter’s Five Force Analysis

7.7. Impact of Covid-19 on IVD Quality Control Market

8.    Japan IVD Quality Control Market Analysis and Forecasts, 2023 - 2031

8.1. Overview

8.1.1. Japan IVD Quality Control Market Revenue (US$ Mn)

8.2. Japan IVD Quality Control Market Revenue (US$ Mn) and  Forecasts, By Offerings

8.2.1. Quality Control Products (Definition, Market Penetration (2019), Market Estimation (2015 - 2022), Market Forecast (2023 - 2031), Compound Annual Growth Rate (CAGR), Regional Bifurcation (Hokkaido, Tohoku, Kanto, Chubu, Kinki/Kansai, Chugoku, Shikoku, Kyushu (incl. Okinawa)) and Information on Serum Based, Whole Blood, Urine)

8.2.1.1.    Serum Based

8.2.1.2.    Whole Blood

8.2.1.3.    Urine

8.2.2. Data Management Solutions

8.2.2.1.    Definition

8.2.2.2.    Market Estimation and Penetration, 2015 - 2022

8.2.2.3.    Market Forecast, 2023 - 2031

8.2.2.4.    Compound Annual Growth Rate (CAGR)

8.2.2.5.    Regional Bifurcation

8.2.2.5.1.    Hokkaido

8.2.2.5.1.1. Market Estimation, 2015 – 2022

8.2.2.5.1.2. Market Forecast, 2023 – 2031

8.2.2.5.2.    Tohoku

8.2.2.5.2.1. Market Estimation, 2015 – 2022

8.2.2.5.2.2. Market Forecast, 2023 – 2031

8.2.2.5.3.    Kanto

8.2.2.5.3.1. Market Estimation, 2015 – 2022

8.2.2.5.3.2. Market Forecast, 2023 – 2031

8.2.2.5.4.    Chubu

8.2.2.5.4.1. Market Estimation, 2015 – 2022

8.2.2.5.4.2. Market Forecast, 2023 – 2031

8.2.2.5.5.    Kinki/Kansai

8.2.2.5.5.1. Market Estimation, 2015 – 2022

8.2.2.5.5.2. Market Forecast, 2023 – 2031

8.2.2.5.6.    Chugoku

8.2.2.5.6.1. Market Estimation, 2015 – 2022

8.2.2.5.6.2. Market Forecast, 2023 – 2031

8.2.2.5.7.    Shikoku

8.2.2.5.7.1. Market Estimation, 2015 – 2022

8.2.2.5.7.2. Market Forecast, 2023 – 2031

8.2.2.5.8.    Kyushu (incl. Okinawa)

8.2.2.5.8.1. Market Estimation, 2015 – 2022

8.2.2.5.8.2. Market Forecast, 2023 – 2031

8.2.3. Quality Assurance Services

8.2.3.1.    Definition

8.2.3.2.    Market Estimation and Penetration, 2015 - 2022

8.2.3.3.    Market Forecast, 2023 - 2031

8.2.3.4.    Compound Annual Growth Rate (CAGR)

8.2.3.5.    Regional Bifurcation

8.2.3.5.1.    Hokkaido

8.2.3.5.1.1. Market Estimation, 2015 – 2022

8.2.3.5.1.2. Market Forecast, 2023 – 2031

8.2.3.5.2.    Tohoku

8.2.3.5.2.1. Market Estimation, 2015 – 2022

8.2.3.5.2.2. Market Forecast, 2023 – 2031

8.2.3.5.3.    Kanto

8.2.3.5.3.1. Market Estimation, 2015 – 2022

8.2.3.5.3.2. Market Forecast, 2023 – 2031

8.2.3.5.4.    Chubu

8.2.3.5.4.1. Market Estimation, 2015 – 2022

8.2.3.5.4.2. Market Forecast, 2023 – 2031

8.2.3.5.5.    Kinki/Kansai

8.2.3.5.5.1. Market Estimation, 2015 – 2022

8.2.3.5.5.2. Market Forecast, 2023 – 2031

8.2.3.5.6.    Chugoku

8.2.3.5.6.1. Market Estimation, 2015 – 2022

8.2.3.5.6.2. Market Forecast, 2023 – 2031

8.2.3.5.7.    Shikoku

8.2.3.5.7.1. Market Estimation, 2015 – 2022

8.2.3.5.7.2. Market Forecast, 2023 – 2031

8.2.3.5.8.    Kyushu (incl. Okinawa)

8.2.3.5.8.1. Market Estimation, 2015 – 2022

8.2.3.5.8.2. Market Forecast, 2023 – 2031

8.3. Key Segment for Channeling Investments

8.3.1. By Offerings

9.    Japan IVD Quality Control Market Analysis and Forecasts, 2023 - 2031

9.1. Overview

9.2. Japan IVD Quality Control Market Revenue (US$ Mn) and  Forecasts, By Control (Analytes)

9.2.1. Immunochemistry

9.2.1.1.    Definition

9.2.1.2.    Market Estimation and Penetration, 2015 - 2022

9.2.1.3.    Market Forecast, 2023 - 2031

9.2.1.4.    Compound Annual Growth Rate (CAGR)

9.2.1.5.    Regional Bifurcation

9.2.1.5.1.    Hokkaido

9.2.1.5.1.1. Market Estimation, 2015 – 2022

9.2.1.5.1.2. Market Forecast, 2023 – 2031

9.2.1.5.2.    Tohoku

9.2.1.5.2.1. Market Estimation, 2015 – 2022

9.2.1.5.2.2. Market Forecast, 2023 – 2031

9.2.1.5.3.    Kanto

9.2.1.5.3.1. Market Estimation, 2015 – 2022

9.2.1.5.3.2. Market Forecast, 2023 – 2031

9.2.1.5.4.    Chubu

9.2.1.5.4.1. Market Estimation, 2015 – 2022

9.2.1.5.4.2. Market Forecast, 2023 – 2031

9.2.1.5.5.    Kinki/Kansai

9.2.1.5.5.1. Market Estimation, 2015 – 2022

9.2.1.5.5.2. Market Forecast, 2023 – 2031

9.2.1.5.6.    Chugoku

9.2.1.5.6.1. Market Estimation, 2015 – 2022

9.2.1.5.6.2. Market Forecast, 2023 – 2031

9.2.1.5.7.    Shikoku

9.2.1.5.7.1. Market Estimation, 2015 – 2022

9.2.1.5.7.2. Market Forecast, 2023 – 2031

9.2.1.5.8.    Kyushu (incl. Okinawa)

9.2.1.5.8.1. Market Estimation, 2015 – 2022

9.2.1.5.8.2. Market Forecast, 2023 – 2031

9.2.2. Clinical Chemistry

9.2.2.1.    Definition

9.2.2.2.    Market Estimation and Penetration, 2015 - 2022

9.2.2.3.    Market Forecast, 2023 - 2031

9.2.2.4.    Compound Annual Growth Rate (CAGR)

9.2.2.5.    Regional Bifurcation

9.2.2.5.1.    Hokkaido

9.2.2.5.1.1. Market Estimation, 2015 – 2022

9.2.2.5.1.2. Market Forecast, 2023 – 2031

9.2.2.5.2.    Tohoku

9.2.2.5.2.1. Market Estimation, 2015 – 2022

9.2.2.5.2.2. Market Forecast, 2023 – 2031

9.2.2.5.3.    Kanto

9.2.2.5.3.1. Market Estimation, 2015 – 2022

9.2.2.5.3.2. Market Forecast, 2023 – 2031

9.2.2.5.4.    Chubu

9.2.2.5.4.1. Market Estimation, 2015 – 2022

9.2.2.5.4.2. Market Forecast, 2023 – 2031

9.2.2.5.5.    Kinki/Kansai

9.2.2.5.5.1. Market Estimation, 2015 – 2022

9.2.2.5.5.2. Market Forecast, 2023 – 2031

9.2.2.5.6.    Chugoku

9.2.2.5.6.1. Market Estimation, 2015 – 2022

9.2.2.5.6.2. Market Forecast, 2023 – 2031

9.2.2.5.7.    Shikoku

9.2.2.5.7.1. Market Estimation, 2015 – 2022

9.2.2.5.7.2. Market Forecast, 2023 – 2031

9.2.2.5.8.    Kyushu (incl. Okinawa)

9.2.2.5.8.1. Market Estimation, 2015 – 2022

9.2.2.5.8.2. Market Forecast, 2023 – 2031

9.2.3. Microbiology

9.2.3.1.    Definition

9.2.3.2.    Market Estimation and Penetration, 2015 - 2022

9.2.3.3.    Market Forecast, 2023 - 2031

9.2.3.4.    Compound Annual Growth Rate (CAGR)

9.2.3.5.    Regional Bifurcation

9.2.3.5.1.    Hokkaido

9.2.3.5.1.1. Market Estimation, 2015 – 2022

9.2.3.5.1.2. Market Forecast, 2023 – 2031

9.2.3.5.2.    Tohoku

9.2.3.5.2.1. Market Estimation, 2015 – 2022

9.2.3.5.2.2. Market Forecast, 2023 – 2031

9.2.3.5.3.    Kanto

9.2.3.5.3.1. Market Estimation, 2015 – 2022

9.2.3.5.3.2. Market Forecast, 2023 – 2031

9.2.3.5.4.    Chubu

9.2.3.5.4.1. Market Estimation, 2015 – 2022

9.2.3.5.4.2. Market Forecast, 2023 – 2031

9.2.3.5.5.    Kinki/Kansai

9.2.3.5.5.1. Market Estimation, 2015 – 2022

9.2.3.5.5.2. Market Forecast, 2023 – 2031

9.2.3.5.6.    Chugoku

9.2.3.5.6.1. Market Estimation, 2015 – 2022

9.2.3.5.6.2. Market Forecast, 2023 – 2031

9.2.3.5.7.    Shikoku

9.2.3.5.7.1. Market Estimation, 2015 – 2022

9.2.3.5.7.2. Market Forecast, 2023 – 2031

9.2.3.5.8.    Kyushu (incl. Okinawa)

9.2.3.5.8.1. Market Estimation, 2015 – 2022

9.2.3.5.8.2. Market Forecast, 2023 – 2031

9.2.4. Hematology

9.2.4.1.    Definition

9.2.4.2.    Market Estimation and Penetration, 2015 - 2022

9.2.4.3.    Market Forecast, 2023 - 2031

9.2.4.4.    Compound Annual Growth Rate (CAGR)

9.2.4.5.    Regional Bifurcation

9.2.4.5.1.    Hokkaido

9.2.4.5.1.1. Market Estimation, 2015 – 2022

9.2.4.5.1.2. Market Forecast, 2023 – 2031

9.2.4.5.2.    Tohoku

9.2.4.5.2.1. Market Estimation, 2015 – 2022

9.2.4.5.2.2. Market Forecast, 2023 – 2031

9.2.4.5.3.    Kanto

9.2.4.5.3.1. Market Estimation, 2015 – 2022

9.2.4.5.3.2. Market Forecast, 2023 – 2031

9.2.4.5.4.    Chubu

9.2.4.5.4.1. Market Estimation, 2015 – 2022

9.2.4.5.4.2. Market Forecast, 2023 – 2031

9.2.4.5.5.    Kinki/Kansai

9.2.4.5.5.1. Market Estimation, 2015 – 2022

9.2.4.5.5.2. Market Forecast, 2023 – 2031

9.2.4.5.6.    Chugoku

9.2.4.5.6.1. Market Estimation, 2015 – 2022

9.2.4.5.6.2. Market Forecast, 2023 – 2031

9.2.4.5.7.    Shikoku

9.2.4.5.7.1. Market Estimation, 2015 – 2022

9.2.4.5.7.2. Market Forecast, 2023 – 2031

9.2.4.5.8.    Kyushu (incl. Okinawa)

9.2.4.5.8.1. Market Estimation, 2015 – 2022

9.2.4.5.8.2. Market Forecast, 2023 – 2031

9.2.5. Coagulation

9.2.5.1.    Definition

9.2.5.2.    Market Estimation and Penetration, 2015 - 2022

9.2.5.3.    Market Forecast, 2023 - 2031

9.2.5.4.    Compound Annual Growth Rate (CAGR)

9.2.5.5.    Regional Bifurcation

9.2.5.5.1.    Hokkaido

9.2.5.5.1.1. Market Estimation, 2015 – 2022

9.2.5.5.1.2. Market Forecast, 2023 – 2031

9.2.5.5.2.    Tohoku

9.2.5.5.2.1. Market Estimation, 2015 – 2022

9.2.5.5.2.2. Market Forecast, 2023 – 2031

9.2.5.5.3.    Kanto

9.2.5.5.3.1. Market Estimation, 2015 – 2022

9.2.5.5.3.2. Market Forecast, 2023 – 2031

9.2.5.5.4.    Chubu

9.2.5.5.4.1. Market Estimation, 2015 – 2022

9.2.5.5.4.2. Market Forecast, 2023 – 2031

9.2.5.5.5.    Kinki/Kansai

9.2.5.5.5.1. Market Estimation, 2015 – 2022

9.2.5.5.5.2. Market Forecast, 2023 – 2031

9.2.5.5.6.    Chugoku

9.2.5.5.6.1. Market Estimation, 2015 – 2022

9.2.5.5.6.2. Market Forecast, 2023 – 2031

9.2.5.5.7.    Shikoku

9.2.5.5.7.1. Market Estimation, 2015 – 2022

9.2.5.5.7.2. Market Forecast, 2023 – 2031

9.2.5.5.8.    Kyushu (incl. Okinawa)

9.2.5.5.8.1. Market Estimation, 2015 – 2022

9.2.5.5.8.2. Market Forecast, 2023 – 2031

9.2.6. Infectious Disease

9.2.6.1.    Definition

9.2.6.2.    Market Estimation and Penetration, 2015 - 2022

9.2.6.3.    Market Forecast, 2023 - 2031

9.2.6.4.    Compound Annual Growth Rate (CAGR)

9.2.6.5.    Regional Bifurcation

9.2.6.5.1.    Hokkaido

9.2.6.5.1.1. Market Estimation, 2015 – 2022

9.2.6.5.1.2. Market Forecast, 2023 – 2031

9.2.6.5.2.    Tohoku

9.2.6.5.2.1. Market Estimation, 2015 – 2022

9.2.6.5.2.2. Market Forecast, 2023 – 2031

9.2.6.5.3.    Kanto

9.2.6.5.3.1. Market Estimation, 2015 – 2022

9.2.6.5.3.2. Market Forecast, 2023 – 2031

9.2.6.5.4.    Chubu

9.2.6.5.4.1. Market Estimation, 2015 – 2022

9.2.6.5.4.2. Market Forecast, 2023 – 2031

9.2.6.5.5.    Kinki/Kansai

9.2.6.5.5.1. Market Estimation, 2015 – 2022

9.2.6.5.5.2. Market Forecast, 2023 – 2031

9.2.6.5.6.    Chugoku

9.2.6.5.6.1. Market Estimation, 2015 – 2022

9.2.6.5.6.2. Market Forecast, 2023 – 2031

9.2.6.5.7.    Shikoku

9.2.6.5.7.1. Market Estimation, 2015 – 2022

9.2.6.5.7.2. Market Forecast, 2023 – 2031

9.2.6.5.8.    Kyushu (incl. Okinawa)

9.2.6.5.8.1. Market Estimation, 2015 – 2022

9.2.6.5.8.2. Market Forecast, 2023 – 2031

9.2.7. Diabetics/ Hemoglobin

9.2.7.1.    Definition

9.2.7.2.    Market Estimation and Penetration, 2015 - 2022

9.2.7.3.    Market Forecast, 2023 - 2031

9.2.7.4.    Compound Annual Growth Rate (CAGR)

9.2.7.5.    Regional Bifurcation

9.2.7.5.1.    Hokkaido

9.2.7.5.1.1. Market Estimation, 2015 – 2022

9.2.7.5.1.2. Market Forecast, 2023 – 2031

9.2.7.5.2.    Tohoku

9.2.7.5.2.1. Market Estimation, 2015 – 2022

9.2.7.5.2.2. Market Forecast, 2023 – 2031

9.2.7.5.3.    Kanto

9.2.7.5.3.1. Market Estimation, 2015 – 2022

9.2.7.5.3.2. Market Forecast, 2023 – 2031

9.2.7.5.4.    Chubu

9.2.7.5.4.1. Market Estimation, 2015 – 2022

9.2.7.5.4.2. Market Forecast, 2023 – 2031

9.2.7.5.5.    Kinki/Kansai

9.2.7.5.5.1. Market Estimation, 2015 – 2022

9.2.7.5.5.2. Market Forecast, 2023 – 2031

9.2.7.5.6.    Chugoku

9.2.7.5.6.1. Market Estimation, 2015 – 2022

9.2.7.5.6.2. Market Forecast, 2023 – 2031

9.2.7.5.7.    Shikoku

9.2.7.5.7.1. Market Estimation, 2015 – 2022

9.2.7.5.7.2. Market Forecast, 2023 – 2031

9.2.7.5.8.    Kyushu (incl. Okinawa)

9.2.7.5.8.1. Market Estimation, 2015 – 2022

9.2.7.5.8.2. Market Forecast, 2023 – 2031

9.2.8. Cardiology

9.2.8.1.    Definition

9.2.8.2.    Market Estimation and Penetration, 2015 - 2022

9.2.8.3.    Market Forecast, 2023 - 2031

9.2.8.4.    Compound Annual Growth Rate (CAGR)

9.2.8.5.    Regional Bifurcation

9.2.8.5.1.    Hokkaido

9.2.8.5.1.1. Market Estimation, 2015 – 2022

9.2.8.5.1.2. Market Forecast, 2023 – 2031

9.2.8.5.2.    Tohoku

9.2.8.5.2.1. Market Estimation, 2015 – 2022

9.2.8.5.2.2. Market Forecast, 2023 – 2031

9.2.8.5.3.    Kanto

9.2.8.5.3.1. Market Estimation, 2015 – 2022

9.2.8.5.3.2. Market Forecast, 2023 – 2031

9.2.8.5.4.    Chubu

9.2.8.5.4.1. Market Estimation, 2015 – 2022

9.2.8.5.4.2. Market Forecast, 2023 – 2031

9.2.8.5.5.    Kinki/Kansai

9.2.8.5.5.1. Market Estimation, 2015 – 2022

9.2.8.5.5.2. Market Forecast, 2023 – 2031

9.2.8.5.6.    Chugoku

9.2.8.5.6.1. Market Estimation, 2015 – 2022

9.2.8.5.6.2. Market Forecast, 2023 – 2031

9.2.8.5.7.    Shikoku

9.2.8.5.7.1. Market Estimation, 2015 – 2022

9.2.8.5.7.2. Market Forecast, 2023 – 2031

9.2.8.5.8.    Kyushu (incl. Okinawa)

9.2.8.5.8.1. Market Estimation, 2015 – 2022

9.2.8.5.8.2. Market Forecast, 2023 – 2031

9.2.9. Others

9.2.9.1.    Definition

9.2.9.2.    Market Estimation and Penetration, 2015 - 2022

9.2.9.3.    Market Forecast, 2023 - 2031

9.2.9.4.    Compound Annual Growth Rate (CAGR)

9.3. Key Segment for Channeling Investments

9.3.1. By Control (Analytes)

10. Japan IVD Quality Control Market Analysis and Forecasts, 2023 - 2031

10.1. Overview

10.2. Japan IVD Quality Control Market Revenue (US$ Mn) and  Forecasts, By Manufacturer Type

10.2.1. Dependent/first-party controls

10.2.1.1.  Definition

10.2.1.2.  Market Estimation and Penetration, 2015 - 2022

10.2.1.3.  Market Forecast, 2023 - 2031

10.2.1.4.  Compound Annual Growth Rate (CAGR)

10.2.1.5.  Regional Bifurcation

10.2.1.5.1.  Hokkaido

10.2.1.5.1.1. Market Estimation, 2015 – 2022

10.2.1.5.1.2. Market Forecast, 2023 – 2031

10.2.1.5.2.  Tohoku

10.2.1.5.2.1. Market Estimation, 2015 – 2022

10.2.1.5.2.2. Market Forecast, 2023 – 2031

10.2.1.5.3.  Kanto

10.2.1.5.3.1. Market Estimation, 2015 – 2022

10.2.1.5.3.2. Market Forecast, 2023 – 2031

10.2.1.5.4.  Chubu

10.2.1.5.4.1. Market Estimation, 2015 – 2022

10.2.1.5.4.2. Market Forecast, 2023 – 2031

10.2.1.5.5.  Kinki/Kansai

10.2.1.5.5.1. Market Estimation, 2015 – 2022

10.2.1.5.5.2. Market Forecast, 2023 – 2031

10.2.1.5.6.  Chugoku

10.2.1.5.6.1. Market Estimation, 2015 – 2022

10.2.1.5.6.2. Market Forecast, 2023 – 2031

10.2.1.5.7.  Shikoku

10.2.1.5.7.1. Market Estimation, 2015 – 2022

10.2.1.5.7.2. Market Forecast, 2023 – 2031

10.2.1.5.8.  Kyushu (incl. Okinawa)

10.2.1.5.8.1. Market Estimation, 2015 – 2022

10.2.1.5.8.2. Market Forecast, 2023 – 2031

10.2.2. Independent/third party controls

10.2.2.1.  Definition

10.2.2.2.  Market Estimation and Penetration, 2015 - 2022

10.2.2.3.  Market Forecast, 2023 - 2031

10.2.2.4.  Compound Annual Growth Rate (CAGR)

10.2.2.5.  Regional Bifurcation

10.2.2.5.1.  Hokkaido

10.2.2.5.1.1. Market Estimation, 2015 – 2022

10.2.2.5.1.2. Market Forecast, 2023 – 2031

10.2.2.5.2.  Tohoku

10.2.2.5.2.1. Market Estimation, 2015 – 2022

10.2.2.5.2.2. Market Forecast, 2023 – 2031

10.2.2.5.3.  Kanto

10.2.2.5.3.1. Market Estimation, 2015 – 2022

10.2.2.5.3.2. Market Forecast, 2023 – 2031

10.2.2.5.4.  Chubu

10.2.2.5.4.1. Market Estimation, 2015 – 2022

10.2.2.5.4.2. Market Forecast, 2023 – 2031

10.2.2.5.5.  Kinki/Kansai

10.2.2.5.5.1. Market Estimation, 2015 – 2022

10.2.2.5.5.2. Market Forecast, 2023 – 2031

10.2.2.5.6.  Chugoku

10.2.2.5.6.1. Market Estimation, 2015 – 2022

10.2.2.5.6.2. Market Forecast, 2023 – 2031

10.2.2.5.7.  Shikoku

10.2.2.5.7.1. Market Estimation, 2015 – 2022

10.2.2.5.7.2. Market Forecast, 2023 – 2031

10.2.2.5.8.  Kyushu (incl. Okinawa)

10.2.2.5.8.1. Market Estimation, 2015 – 2022

10.2.2.5.8.2. Market Forecast, 2023 – 2031

10.3. Key Segment for Channeling Investments

10.3.1. By Manufacturer Type

11. Japan IVD Quality Control Market Analysis and Forecasts, 2023 - 2031

11.1. Overview

11.2. Japan IVD Quality Control Market Revenue (US$ Mn) and  Forecasts, By End Users

11.2.1. Hospitals and Clinics

11.2.1.1.  Definition

11.2.1.2.  Market Estimation and Penetration, 2015 - 2022

11.2.1.3.  Market Forecast, 2023 - 2031

11.2.1.4.  Compound Annual Growth Rate (CAGR)

11.2.1.5.  Regional Bifurcation

11.2.1.5.1.  Hokkaido

11.2.1.5.1.1. Market Estimation, 2015 – 2022

11.2.1.5.1.2. Market Forecast, 2023 – 2031

11.2.1.5.2.  Tohoku

11.2.1.5.2.1. Market Estimation, 2015 – 2022

11.2.1.5.2.2. Market Forecast, 2023 – 2031

11.2.1.5.3.  Kanto

11.2.1.5.3.1. Market Estimation, 2015 – 2022

11.2.1.5.3.2. Market Forecast, 2023 – 2031

11.2.1.5.4.  Chubu

11.2.1.5.4.1. Market Estimation, 2015 – 2022

11.2.1.5.4.2. Market Forecast, 2023 – 2031

11.2.1.5.5.  Kinki/Kansai

11.2.1.5.5.1. Market Estimation, 2015 – 2022

11.2.1.5.5.2. Market Forecast, 2023 – 2031

11.2.1.5.6.  Chugoku

11.2.1.5.6.1. Market Estimation, 2015 – 2022

11.2.1.5.6.2. Market Forecast, 2023 – 2031

11.2.1.5.7.  Shikoku

11.2.1.5.7.1. Market Estimation, 2015 – 2022

11.2.1.5.7.2. Market Forecast, 2023 – 2031

11.2.1.5.8.  Kyushu (incl. Okinawa)

11.2.1.5.8.1. Market Estimation, 2015 – 2022

11.2.1.5.8.2. Market Forecast, 2023 – 2031

11.2.2. Laboratories

11.2.2.1.  Definition

11.2.2.2.  Market Estimation and Penetration, 2015 - 2022

11.2.2.3.  Market Forecast, 2023 - 2031

11.2.2.4.  Compound Annual Growth Rate (CAGR)

11.2.2.5.  Regional Bifurcation

11.2.2.5.1.  Hokkaido

11.2.2.5.1.1. Market Estimation, 2015 – 2022

11.2.2.5.1.2. Market Forecast, 2023 – 2031

11.2.2.5.2.  Tohoku

11.2.2.5.2.1. Market Estimation, 2015 – 2022

11.2.2.5.2.2. Market Forecast, 2023 – 2031

11.2.2.5.3.  Kanto

11.2.2.5.3.1. Market Estimation, 2015 – 2022

11.2.2.5.3.2. Market Forecast, 2023 – 2031

11.2.2.5.4.  Chubu

11.2.2.5.4.1. Market Estimation, 2015 – 2022

11.2.2.5.4.2. Market Forecast, 2023 – 2031

11.2.2.5.5.  Kinki/Kansai

11.2.2.5.5.1. Market Estimation, 2015 – 2022

11.2.2.5.5.2. Market Forecast, 2023 – 2031

11.2.2.5.6.  Chugoku

11.2.2.5.6.1. Market Estimation, 2015 – 2022

11.2.2.5.6.2. Market Forecast, 2023 – 2031

11.2.2.5.7.  Shikoku

11.2.2.5.7.1. Market Estimation, 2015 – 2022

11.2.2.5.7.2. Market Forecast, 2023 – 2031

11.2.2.5.8.  Kyushu (incl. Okinawa)

11.2.2.5.8.1. Market Estimation, 2015 – 2022

11.2.2.5.8.2. Market Forecast, 2023 – 2031

11.2.3. Research Institutes

11.2.3.1.  Definition

11.2.3.2.  Market Estimation and Penetration, 2015 - 2022

11.2.3.3.  Market Forecast, 2023 - 2031

11.2.3.4.  Compound Annual Growth Rate (CAGR)

11.2.3.5.  Regional Bifurcation

11.2.3.5.1.  Hokkaido

11.2.3.5.1.1. Market Estimation, 2015 – 2022

11.2.3.5.1.2. Market Forecast, 2023 – 2031

11.2.3.5.2.  Tohoku

11.2.3.5.2.1. Market Estimation, 2015 – 2022

11.2.3.5.2.2. Market Forecast, 2023 – 2031

11.2.3.5.3.  Kanto

11.2.3.5.3.1. Market Estimation, 2015 – 2022

11.2.3.5.3.2. Market Forecast, 2023 – 2031

11.2.3.5.4.  Chubu

11.2.3.5.4.1. Market Estimation, 2015 – 2022

11.2.3.5.4.2. Market Forecast, 2023 – 2031

11.2.3.5.5.  Kinki/Kansai

11.2.3.5.5.1. Market Estimation, 2015 – 2022

11.2.3.5.5.2. Market Forecast, 2023 – 2031

11.2.3.5.6.  Chugoku

11.2.3.5.6.1. Market Estimation, 2015 – 2022

11.2.3.5.6.2. Market Forecast, 2023 – 2031

11.2.3.5.7.  Shikoku

11.2.3.5.7.1. Market Estimation, 2015 – 2022

11.2.3.5.7.2. Market Forecast, 2023 – 2031

11.2.3.5.8.  Kyushu (incl. Okinawa)

11.2.3.5.8.1. Market Estimation, 2015 – 2022

11.2.3.5.8.2. Market Forecast, 2023 – 2031

11.2.4. Others

11.2.4.1.  Definition

11.2.4.2.  Market Estimation and Penetration, 2015 - 2022

11.2.4.3.  Market Forecast, 2023 - 2031

11.2.4.4.  Compound Annual Growth Rate (CAGR)

11.2.4.5.  Regional Bifurcation

11.2.4.5.1.  Hokkaido

11.2.4.5.1.1. Market Estimation, 2015 – 2022

11.2.4.5.1.2. Market Forecast, 2023 – 2031

11.2.4.5.2.  Tohoku

11.2.4.5.2.1. Market Estimation, 2015 – 2022

11.2.4.5.2.2. Market Forecast, 2023 – 2031

11.2.4.5.3.  Kanto

11.2.4.5.3.1. Market Estimation, 2015 – 2022

11.2.4.5.3.2. Market Forecast, 2023 – 2031

11.2.4.5.4.  Chubu

11.2.4.5.4.1. Market Estimation, 2015 – 2022

11.2.4.5.4.2. Market Forecast, 2023 – 2031

11.2.4.5.5.  Kinki/Kansai

11.2.4.5.5.1. Market Estimation, 2015 – 2022

11.2.4.5.5.2. Market Forecast, 2023 – 2031

11.2.4.5.6.  Chugoku

11.2.4.5.6.1. Market Estimation, 2015 – 2022

11.2.4.5.6.2. Market Forecast, 2023 – 2031

11.2.4.5.7.  Shikoku

11.2.4.5.7.1. Market Estimation, 2015 – 2022

11.2.4.5.7.2. Market Forecast, 2023 – 2031

11.2.4.5.8.  Kyushu (incl. Okinawa)

11.2.4.5.8.1. Market Estimation, 2015 – 2022

11.2.4.5.8.2. Market Forecast, 2023 – 2031

11.3. Key Segment for Channeling Investments

11.3.1. By End Users

12. Japan IVD Quality Control Market Analysis and Forecasts, 2023 - 2031

12.1. Overview

12.2. Japan IVD Quality Control Market Analysis and Forecasts, by Region

12.2.1. Hokkaido

12.2.1.1.  Hokkaido IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Offerings

12.2.1.1.1.  Quality Control Products

12.2.1.1.1.1. Serum Based

12.2.1.1.1.2. Whole Blood

12.2.1.1.1.3. Urine

12.2.1.1.2.  Data Management Solutions

12.2.1.1.3.  Quality Assurance Services

12.2.1.2.  Hokkaido IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Control (Analytes)

12.2.1.2.1.  Immunochemistry

12.2.1.2.2.  Clinical Chemistry

12.2.1.2.3.  Microbiology

12.2.1.2.4.  Hematology

12.2.1.2.5.  Coagulation

12.2.1.2.6.  Infectious Disease

12.2.1.2.7.  Diabetics/ Hemoglobin

12.2.1.2.8.  Cardiology

12.2.1.2.9.  Others

12.2.1.3.  Hokkaido IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Manufacturer Type

12.2.1.3.1.  Dependent/first-party controls

12.2.1.3.2.  Independent/third party controls

12.2.1.4.  Hokkaido IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By End Users

12.2.1.4.1.  Hospitals and Clinics

12.2.1.4.2.   Laboratories

12.2.1.4.3.  Research Institutes

12.2.1.4.4.  Others

12.2.2. Tohoku

12.2.2.1.  Tohoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Offerings

12.2.2.1.1.  Quality Control Products

12.2.2.1.1.1. Serum Based

12.2.2.1.1.2. Whole Blood

12.2.2.1.1.3. Urine

12.2.2.1.2.  Data Management Solutions

12.2.2.1.3.  Quality Assurance Services

12.2.2.2.  Tohoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Control (Analytes)

12.2.2.2.1.  Immunochemistry

12.2.2.2.2.  Clinical Chemistry

12.2.2.2.3.  Microbiology

12.2.2.2.4.  Hematology

12.2.2.2.5.  Coagulation

12.2.2.2.6.  Infectious Disease

12.2.2.2.7.  Diabetics/ Hemoglobin

12.2.2.2.8.  Cardiology

12.2.2.2.9.  Others

12.2.2.3.  Tohoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Manufacturer Type

12.2.2.3.1.  Dependent/first-party controls

12.2.2.3.2.  Independent/third party controls

12.2.2.4.  Tohoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By End Users

12.2.2.4.1.  Hospitals and Clinics

12.2.2.4.2.  Laboratories

12.2.2.4.3.  Research Institutes

12.2.2.4.4.  Others

12.2.3. Kanto

12.2.3.1.  Kanto IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Offerings

12.2.3.1.1.  Quality Control Products

12.2.3.1.1.1. Serum Based

12.2.3.1.1.2. Whole Blood

12.2.3.1.1.3. Urine

12.2.3.1.2.  Data Management Solutions

12.2.3.1.3.  Quality Assurance Services

12.2.3.2.  Kanto IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Control (Analytes)

12.2.3.2.1.  Immunochemistry

12.2.3.2.2.  Clinical Chemistry

12.2.3.2.3.  Microbiology

12.2.3.2.4.  Hematology

12.2.3.2.5.  Coagulation

12.2.3.2.6.  Infectious Disease

12.2.3.2.7.  Diabetics/ Hemoglobin

12.2.3.2.8.  Cardiology

12.2.3.2.9.  Others

12.2.3.3.  Kanto IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Manufacturer Type

12.2.3.3.1.  Dependent/first-party controls

12.2.3.3.2.  Independent/third party controls

12.2.3.4.  Kanto IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By End Users

12.2.3.4.1.  Hospitals and Clinics

12.2.3.4.2.  Laboratories

12.2.3.4.3.  Research Institutes

12.2.3.4.4.  Others

12.2.4. Chubu

12.2.4.1.  Chubu IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Offerings

12.2.4.1.1.  Quality Control Products

12.2.4.1.1.1. Serum Based

12.2.4.1.1.2. Whole Blood

12.2.4.1.1.3. Urine

12.2.4.1.2.  Data Management Solutions

12.2.4.1.3.  Quality Assurance Services

12.2.4.2.  Chubu IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Control (Analytes)

12.2.4.2.1.  Immunochemistry

12.2.4.2.2.  Clinical Chemistry

12.2.4.2.3.  Microbiology

12.2.4.2.4.  Hematology

12.2.4.2.5.  Coagulation

12.2.4.2.6.  Infectious Disease

12.2.4.2.7.  Diabetics/ Hemoglobin

12.2.4.2.8.  Cardiology

12.2.4.2.9.  Others

12.2.4.3.  Chubu IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Manufacturer Type

12.2.4.3.1.  Dependent/first-party controls

12.2.4.3.2.  Independent/third party controls

12.2.4.4.  Chubu IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By End Users

12.2.4.4.1.  Hospitals and Clinics

12.2.4.4.2.  Laboratories

12.2.4.4.3.  Research Institutes

12.2.4.4.4.  Others

12.2.5. Kinki/Kansai

12.2.5.1.  Kinki/Kansai IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Offerings

12.2.5.1.1.  Quality Control Products

12.2.5.1.1.1. Serum Based

12.2.5.1.1.2. Whole Blood

12.2.5.1.1.3. Urine

12.2.5.1.2.  Data Management Solutions

12.2.5.1.3.  Quality Assurance Services

12.2.5.2.  Kinki/Kansai IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Control (Analytes)

12.2.5.2.1.  Immunochemistry

12.2.5.2.2.  Clinical Chemistry

12.2.5.2.3.  Microbiology

12.2.5.2.4.  Hematology

12.2.5.2.5.  Coagulation

12.2.5.2.6.  Infectious Disease

12.2.5.2.7.  Diabetics/ Hemoglobin

12.2.5.2.8.  Cardiology

12.2.5.2.9.  Others

12.2.5.3.  Kinki/Kansai IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Manufacturer Type

12.2.5.3.1.  Dependent/first-party controls

12.2.5.3.2.  Independent/third party controls

12.2.5.4.  Kinki/Kansai IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By End Users

12.2.5.4.1.  Hospitals and Clinics

12.2.5.4.2.  Laboratories

12.2.5.4.3.  Research Institutes

12.2.5.4.4.  Others

12.2.6. Chugoku

12.2.6.1.  Chugoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Offerings

12.2.6.1.1.  Quality Control Products

12.2.6.1.1.1. Serum Based

12.2.6.1.1.2. Whole Blood

12.2.6.1.1.3. Urine

12.2.6.1.2.  Data Management Solutions

12.2.6.1.3.  Quality Assurance Services

12.2.6.2.  Chugoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Control (Analytes)

12.2.6.2.1.  Immunochemistry

12.2.6.2.2.  Clinical Chemistry

12.2.6.2.3.  Microbiology

12.2.6.2.4.  Hematology

12.2.6.2.5.  Coagulation

12.2.6.2.6.  Infectious Disease

12.2.6.2.7.  Diabetics/ Hemoglobin

12.2.6.2.8.  Cardiology

12.2.6.2.9.  Others

12.2.6.3.  Chugoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Manufacturer Type

12.2.6.3.1.  Dependent/first-party controls

12.2.6.3.2.  Independent/third party controls

12.2.6.4.  Chugoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By End Users

12.2.6.4.1.  Hospitals and Clinics

12.2.6.4.2.  Laboratories

12.2.6.4.3.  Research Institutes

12.2.6.4.4.  Others

12.2.7. Shikoku

12.2.7.1.  Shikoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Offerings

12.2.7.1.1.  Quality Control Products

12.2.7.1.1.1. Serum Based

12.2.7.1.1.2. Whole Blood

12.2.7.1.1.3. Urine

12.2.7.1.2.  Data Management Solutions

12.2.7.1.3.  Quality Assurance Services

12.2.7.2.  Shikoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Control (Analytes)

12.2.7.2.1.  Immunochemistry

12.2.7.2.2.  Clinical Chemistry

12.2.7.2.3.  Microbiology

12.2.7.2.4.  Hematology

12.2.7.2.5.  Coagulation

12.2.7.2.6.  Infectious Disease

12.2.7.2.7.  Diabetics/ Hemoglobin

12.2.7.2.8.  Cardiology

12.2.7.2.9.  Others

12.2.7.3.  Shikoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Manufacturer Type

12.2.7.3.1.  Dependent/first-party controls

12.2.7.3.2.  Independent/third party controls

12.2.7.4.  Shikoku IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By End Users

12.2.7.4.1.  Hospitals and Clinics

12.2.7.4.2.  Laboratories

12.2.7.4.3.  Research Institutes

12.2.7.4.4.  Others

12.2.8. Kyushu (incl. Okinawa)

12.2.8.1.  Kyushu (incl. Okinawa) IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Offerings

12.2.8.1.1.  Quality Control Products

12.2.8.1.1.1. Serum Based

12.2.8.1.1.2. Whole Blood

12.2.8.1.1.3. Urine

12.2.8.1.2.  Data Management Solutions

12.2.8.1.3.  Quality Assurance Services

12.2.8.2.  Kyushu (incl. Okinawa) IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Control (Analytes)

12.2.8.2.1.  Immunochemistry

12.2.8.2.2.  Clinical Chemistry

12.2.8.2.3.  Microbiology

12.2.8.2.4.  Hematology

12.2.8.2.5.  Coagulation

12.2.8.2.6.  Infectious Disease

12.2.8.2.7.  Diabetics/ Hemoglobin

12.2.8.2.8.  Cardiology

12.2.8.2.9.  Others

12.2.8.3.  Kyushu (incl. Okinawa) IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By Manufacturer Type

12.2.8.3.1.  Dependent/first-party controls

12.2.8.3.2.  Independent/third party controls

12.2.8.4.  Kyushu (incl. Okinawa) IVD Quality Control Market Revenue (US$ Mn) and Forecasts, By End Users

12.2.8.4.1.  Hospitals and Clinics

12.2.8.4.2.  Laboratories

12.2.8.4.3.  Research Institutes

12.2.8.4.4.  Others

12.3. Key Segment for Channeling Investments

12.3.1. By Region

13. Competitive Benchmarking

13.1. Market Share Analysis, 2022

13.2. Japan Presence and Growth Strategies

13.2.1. Mergers and Acquisitions

13.2.2. Product Launches

13.2.3. Investments Trends

13.2.4. R&D Initiatives

14. Player Profiles

14.1. Abbott Diagnostics

14.1.1. Company Details

14.1.2. Company Overview

14.1.3. Product Offerings

14.1.4. Key Developments

14.1.5. Financial Analysis

14.1.6. SWOT Analysis

14.1.7. Business Strategies

14.2. Beckman Coulter, Inc.

14.2.1. Company Details

14.2.2. Company Overview

14.2.3. Product Offerings

14.2.4. Key Developments

14.2.5. Financial Analysis

14.2.6. SWOT Analysis

14.2.7. Business Strategies

14.3. Bio-Rad Laboratories, Inc.

14.3.1. Company Details

14.3.2. Company Overview

14.3.3. Product Offerings

14.3.4. Key Developments

14.3.5. Financial Analysis

14.3.6. SWOT Analysis

14.3.7. Business Strategies

14.4. F. Hoffmann-La Roche Ltd

14.4.1. Company Details

14.4.2. Company Overview

14.4.3. Product Offerings

14.4.4. Key Developments

14.4.5. Financial Analysis

14.4.6. SWOT Analysis

14.4.7. Business Strategies

14.5. Fortress Diagnostics

14.5.1. Company Details

14.5.2. Company Overview

14.5.3. Product Offerings

14.5.4. Key Developments

14.5.5. Financial Analysis

14.5.6. SWOT Analysis

14.5.7. Business Strategies

14.6. Fujirebio Inc.

14.6.1. Company Details

14.6.2. Company Overview

14.6.3. Product Offerings

14.6.4. Key Developments

14.6.5. Financial Analysis

14.6.6. SWOT Analysis

14.6.7. Business Strategies

14.7. Horiba Medical Japan Co., Ltd.

14.7.1. Company Details

14.7.2. Company Overview

14.7.3. Product Offerings

14.7.4. Key Developments

14.7.5. Financial Analysis

14.7.6. SWOT Analysis

14.7.7. Business Strategies

14.8. Randox Laboratories

14.8.1. Company Details

14.8.2. Company Overview

14.8.3. Product Offerings

14.8.4. Key Developments

14.8.5. Financial Analysis

14.8.6. SWOT Analysis

14.8.7. Business Strategies

14.9. Sekisui Medical Co., Ltd.

14.9.1. Company Details

14.9.2. Company Overview

14.9.3. Product Offerings

14.9.4. Key Developments

14.9.5. Financial Analysis

14.9.6. SWOT Analysis

14.9.7. Business Strategies

14.10. Sysmex Corporation

14.10.1. Company Details

14.10.2. Company Overview

14.10.3. Product Offerings

14.10.4. Key Developments

14.10.5. Financial Analysis

14.10.6. SWOT Analysis

14.10.7. Business Strategies

14.11. Thermo Fisher Scientific Inc.

14.11.1. Company Details

14.11.2. Company Overview

14.11.3. Product Offerings

14.11.4. Key Developments

14.11.5. Financial Analysis

14.11.6. SWOT Analysis

14.11.7. Business Strategies

14.12. Other Market Participants

15. Key Findings

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

**Exclusive for Multi-User and Enterprise User.

 

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com